ConductScience.org, home

85,013 comparisons from ClinicalTrials.gov.

85,013 comparisons

Most participants first33,758 with no events in either group come last4,241 to 4,260 of 85,013

Show the results as
ComparisonWith the outcomeRisk difference, 95% intervalParticipantsTrial
Intervention vs Control: serious adverse events66 of 1,000

37 of 503

-0.8 points

-3.7 to 1.9

1,503NCT01800201

Automated Hovering to Improve Medication Adherence Among Myocardial Infarction Patients (Heartstrong)

20vPnC vs 13vPnC: serious adverse events44 of 1,000

28 of 503

-1.2 points

-3.8 to 1.1

1,503NCT04379713

20-valent Pneumococcal Conjugate Vaccine Safety Study in Healthy Infants

Gentamicin Group vs Control Group: Proportion of Patients With Superficial Surgical Wound Infections Based on Centers for Disease Control Criteria Adjudicated by an Independent Blinded Committee.49 of 753

46 of 749

0.4 points

-2.1 to 2.9

1,502NCT00600483

Safety and Efficacy of an Antibiotic Implant in Cardiac Surgical Subjects at Higher Risk for Sternal Wound Infection

Gentamicin Group vs Control Group: Proportion of Patients With Deep Surgical Wound Infections Based on Centers for Disease Control Criteria Adjudicated by an Independent Blinded Committee.14 of 753

19 of 749

-0.7 points

-2.3 to 0.9

1,502NCT00600483

Safety and Efficacy of an Antibiotic Implant in Cardiac Surgical Subjects at Higher Risk for Sternal Wound Infection

Gentamicin Group vs Control Group: Rehospitalization for Sternal Wound Infection23 of 753

24 of 749

-0.1 points

-2.0 to 1.7

1,502NCT00600483

Safety and Efficacy of an Antibiotic Implant in Cardiac Surgical Subjects at Higher Risk for Sternal Wound Infection

Gentamicin Group vs Control Group: Surgically Treated Surgical Wound Infection Postoperative Day 9025 of 753

37 of 749

-1.6 points

-3.7 to 0.4

1,502NCT00600483

Safety and Efficacy of an Antibiotic Implant in Cardiac Surgical Subjects at Higher Risk for Sternal Wound Infection

Gentamicin Group vs Control Group: Number of Participants With Surgical Wound Infections From Surgery Through Post-operative Day 9063 of 753

65 of 749

-0.3 points

-3.2 to 2.5

1,502NCT00600483

Safety and Efficacy of an Antibiotic Implant in Cardiac Surgical Subjects at Higher Risk for Sternal Wound Infection

Gentamicin Group vs Control Group: deaths from any cause19 of 743

27 of 759

-1.0 points

-2.8 to 0.8

1,502NCT00600483

Safety and Efficacy of an Antibiotic Implant in Cardiac Surgical Subjects at Higher Risk for Sternal Wound Infection

Gentamicin Group vs Control Group: serious adverse events269 of 743

290 of 759

-2.0 points

-6.9 to 2.9

1,502NCT00600483

Safety and Efficacy of an Antibiotic Implant in Cardiac Surgical Subjects at Higher Risk for Sternal Wound Infection

Empagliflozin vs DPP-4 Inhibitors: Number of Participants With Ketoacidosis1 of 751

1 of 751

0.0 points

-0.6 to 0.6

1,502NCT03764631

Post-authorization Safety Study in Type 2 Diabetic Patients in Saudi Arabia Treated With Empagliflozin to Assess the Incidence of Ketoacidosis, Severe Complications of Urinary Tract Infection, Volume Depletion, and Dehydration

Empagliflozin vs DPP-4 Inhibitors: Number of Participants With Volume Depletion6 of 751

7 of 751

-0.1 points

-1.2 to 0.9

1,502NCT03764631

Post-authorization Safety Study in Type 2 Diabetic Patients in Saudi Arabia Treated With Empagliflozin to Assess the Incidence of Ketoacidosis, Severe Complications of Urinary Tract Infection, Volume Depletion, and Dehydration

Empagliflozin vs DPP-4 Inhibitors: serious adverse events6 of 751

2 of 751

0.5 points

-0.3 to 1.5

1,502NCT03764631

Post-authorization Safety Study in Type 2 Diabetic Patients in Saudi Arabia Treated With Empagliflozin to Assess the Incidence of Ketoacidosis, Severe Complications of Urinary Tract Infection, Volume Depletion, and Dehydration

Tecemotide (L-BLP25) + Cyclophosphamide vs Saline + Placebo: serious adverse events303 of 1,024

151 of 477

-2.1 points

-7.2 to 2.9

1,501NCT00409188

Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)

Nimenrix Group vs Mencevax ACWY Group: Number of Subjects With Grade 3 General Symptoms (Solicited and Unsolicited)10 of 1,125

1 of 376

0.6 points

-0.7 to 1.4

1,501NCT00514904

Non-Inferiority of Meningococcal Vaccine GSK134612 Versus Mencevax™ in 2-10 Year Old Subjects

Nimenrix Group vs Mencevax ACWY Group: Number of Subjects Reporting Any Serious Adverse Events (SAEs)15 of 1,125

7 of 376

-0.5 points

-2.5 to 0.8

1,501NCT00514904

Non-Inferiority of Meningococcal Vaccine GSK134612 Versus Mencevax™ in 2-10 Year Old Subjects

Nimenrix Group vs Mencevax ACWY Group: Number of Subjects Reporting Any Unsolicited Symptoms198 of 1,125

75 of 376

-2.3 points

-7.2 to 2.1

1,501NCT00514904

Non-Inferiority of Meningococcal Vaccine GSK134612 Versus Mencevax™ in 2-10 Year Old Subjects

Nimenrix Group vs Mencevax ACWY Group: serious adverse events15 of 1,125

7 of 376

-0.5 points

-2.5 to 0.8

1,501NCT00514904

Non-Inferiority of Meningococcal Vaccine GSK134612 Versus Mencevax™ in 2-10 Year Old Subjects

MenACWY-CRM vs MenACWY-PS: serious adverse events9 of 950

1 of 550

0.8 points

-0.2 to 1.6

1,500NCT00329849

Safety and Immunogenicity of Meningococcal ACWY Conjugate Versus Polysaccharide Vaccine in Children 2 to 10 Years of Age

Apixaban vs Parenteral Heparin/Oral Vitamin K Antagonist (Usual Care): Number of Participants With Acute Stroke Event0 of 753

6 of 747

-0.8 points

-1.7 to -0.1

1,500NCT02100228

Study Of The Blood Thinner, Apixaban, For Patients Who Have An Abnormal Heart Rhythm (Atrial Fibrillation) And Expected To Have Treatment To Put Them Back Into A Normal Heart Rhythm (Cardioversion)

Apixaban vs Parenteral Heparin/Oral Vitamin K Antagonist (Usual Care): Number of Participants With All Cause Death2 of 753

1 of 747

0.1 points

-0.5 to 0.8

1,500NCT02100228

Study Of The Blood Thinner, Apixaban, For Patients Who Have An Abnormal Heart Rhythm (Atrial Fibrillation) And Expected To Have Treatment To Put Them Back Into A Normal Heart Rhythm (Cardioversion)

Request

GET /api/comparisons/v1

Words from a trial's title, conditions or interventions, its outcome or its groups, or an NCT number.

An outcome counted in participants, the serious adverse events, or the deaths from any cause.

No key needed

Code

Show the call in
curl "https://conductscience.org/api/comparisons/v1?page=213"

Response

The first 2 of this page's 20 results. GET /api/comparisons/v1?page=213

{
  "data": {
    "total": 85013,
    "results": [
      {
        "id": "NCT01800201-sae",
        "title": "Intervention vs Control: serious adverse events",
        "summary": "66 of 1000 against 37 of 503; risk difference -0.8 points, 95% interval -3.7 to 1.9; NCT01800201, Automated Hovering to Improve Medication Adherence Among Myocardial Infarction Patients (Heartstrong)",
        "record": "/library/comparisons/NCT01800201-sae",
        "nct_id": "NCT01800201",
        "kind": "serious-adverse-events",
        "participants": 1503,
        "risk_difference": {
          "value": -0.007558648111332,
          "lower": -0.03715403034698849,
          "upper": 0.01855147235000142
        },
        "group_1": "66 of 1,000",
        "group_2": "37 of 503",
        "difference": "-0.8 points",
        "interval": "-3.7 to 1.9",
        "trial_title": "Automated Hovering to Improve Medication Adherence Among Myocardial Infarction Patients (Heartstrong)"
      },
      {
        "id": "NCT04379713-sae",
        "title": "20vPnC vs 13vPnC: serious adverse events",
        "summary": "44 of 1000 against 28 of 503; risk difference -1.2 points, 95% interval -3.8 to 1.1; NCT04379713, 20-valent Pneumococcal Conjugate Vaccine Safety Study in Healthy Infants",
        "record": "/library/comparisons/NCT04379713-sae",
        "nct_id": "NCT04379713",
        "kind": "serious-adverse-events",
        "participants": 1503,
        "risk_difference": {
          "value": -0.011666003976143147,
          "lower": -0.037739098226233544,
          "upper": 0.010616601037275134
        },
        "group_1": "44 of 1,000",
        "group_2": "28 of 503",
        "difference": "-1.2 points",
        "interval": "-3.8 to 1.1",
        "trial_title": "20-valent Pneumococcal Conjugate Vaccine Safety Study in Healthy Infants"
      }
    ],
    "no_events": 33758,
    "columns": [
      {
        "key": "title",
        "label": "Comparison"
      },
      {
        "key": "group_1",
        "label": "With the outcome",
        "under": "group_2"
      },
      {
        "key": "difference",
        "label": "Risk difference, 95% interval",
        "under": "interval"
      },
      {
        "key": "participants",
        "label": "Participants"
      },
      {
        "key": "nct_id",
        "label": "Trial",
        "under": "trial_title"
      }
    ],
    "order": "Most participants first",
    "kinds": {
      "all": 85013,
      "outcome": 33568,
      "serious-adverse-events": 31897,
      "deaths": 19548
    }
  },
  "release": "trial-comparisons-2026-03-23-0.1.0",
  "terms": [
    {
      "source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
      "license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "Freely available. Acknowledgement requested"
    },
    {
      "source": "ClinicalTrials.gov",
      "license": "none stated",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "No license stated"
    }
  ],
  "next": "/api/comparisons/v1?page=214",
  "request_id": "IPyuOMYd8bBp-Pv4"
}

Ask about these results. The first 10 go in the prompt.

About this data
Holds
85,013 comparisons
From ClinicalTrials.gov. Counted 10 Nov 2026.
Release
23 Mar 2026
trial-comparisons-2026-03-23-0.1.0
Checked
20 of 20 review comparisons traced to ClinicalTrials.gov, and all 510,078 numbers calculated again apart from the builder agree
Access
Open
No account. 60 calls a minute from one address.

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

Genes

NCBI Gene

One gene with its proteins, patents, drugs, trials, grants and papers.

Trials

ClinicalTrials.gov

Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.

Sequences

Patent publications

Paste a sequence and see the patents that disclose it.

Opens sequences.conductscience.org

Drugs and targets

Open Targets

One drug with its targets, the diseases it is studied for, and the trials that name it, with their comparisons, papers and cognitive tests.

For software

Read Trial comparisons from software.

Every answer on this page is also JSON, under /api/comparisons/v1. No key.

GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome

Ask an assistant

  • In FOURIER, how did serious adverse events compare between evolocumab and placebo?
  • Which metformin trials reported deaths, and what was the risk difference?
  • What was the number needed to treat for HELIOS-B's composite outcome?
  • Which placebo-controlled heart failure trials had the most participants?